In addition, TPM4 is a potential target of i-tRF-LeuCAA and is related to epithelial-mesenchymal transition in gliomas.<h4>Conclusions</h4>i-tRF-LeuCAA could be served as a non-invasive biomarker in the diagnosis and prognosis of glioma. Here, TPM4 is linked to central nervous system cancer.